The noncanonical IKK family member TANK-binding kinase 1 (TBK1) is activated by pro-inflammatory cytokines, but its role in controlling metabolism remains unclear. Here, we report that the kinase uniquely controls energy metabolism. Tbk1 expression is increased in adipocytes of HFD-fed mice. Adipocyte-specific TBK1 knockout (ATKO) attenuates HFD-induced obesity by increasing energy expenditure; further studies show that TBK1 directly inhibits AMPK to repress respiration and increase energy storage. Conversely, activation of AMPK under catabolic conditions can increase TBK1 activity through phosphorylation, mediated by AMPK's downstream target ULK1. Surprisingly, ATKO also exaggerates adipose tissue inflammation and insulin resistance. TBK1 suppresses inflammation by phosphorylating and inducing the degradation of the IKK kinase NIK, thus attenuating NF-kB activity. Moreover, TBK1 mediates the negative impact of AMPK activity on NF-kB activation. These data implicate a unique role for TBK1 in mediating bidirectional crosstalk between energy sensing and inflammatory signaling pathways in both over-and undernutrition.
INTRODUCTION
Obesity results from a positive energy balance, when food intake exceeds energy expenditure. Although energy intake and expenditure are tightly coupled to ensure homeostasis (Hall et al., 2012) , even a slight mismatch over time can result in massive weight gain and glucose intolerance. While shortterm nutritional overload is associated with increased energy expenditure in both rodents (Pazos et al., 2015) and humans (Rasmussen et al., 2007) , sustained obesity produces a decrease in energy expenditure (Bachman et al., 2002; Choi et al., 2015; Coleman, 1978; Leibel et al., 1995; Ravussin et al., 1988; Roberts and Leibel, 1998) . Caloric restriction also reduces energy expenditure, resulting in lower basal metabolic rate, in an attempt to defend body weight (Leibel et al., 1995) .
Thus, both over-and undernutrition are associated with reduced energy expenditure.
A great deal of basal energy metabolism occurs in adipose tissue, due to both nonshivering thermogenesis and lipid oxidation (Guilherme et al., 2008) . Among the mechanisms that control energy expenditure are activation of AMP-activated protein kinase (AMPK), a key regulator that senses energy status and responds by increasing lipid oxidation and mitochondrial biogenesis, while reducing lipogenesis and glycogenesis (Daval et al., 2006; Hardie, 2011) . AMPK is a heterotrimeric protein activated by liver kinase B1 (LKB1) via phosphorylation at Thr172 in the AMPKa subunit (Shaw et al., 2004) . The enzyme is also allosterically activated in response to energy stress by sensing an increased AMP/ATP ratio (Hardie et al., 2012; Mihaylova and Shaw, 2011) . Activation of AMPK increases lipid oxidation, represses lipogenesis, and significantly increases mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma co-activator 1a (PGC1a) (Cantó and Auwerx, 2009; Puigserver et al., 1998; Wan et al., 2014) . AMPK can also increase autophagy via phosphorylation and activation of Unc-51-like autophagy-activating kinase 1 (ULK1) (Kim et al., 2011) . The AMPK/ ULK1 axis is required for maintaining mitochondrial homeostasis and also increases the browning of inguinal white adipose tissues (Mottillo et al., 2016) . Moreover, studies have demonstrated a correlation between decreased AMPK activity and increased inflammation (Gauthier et al., 2011) , while activation of AMPK decreases expression of proinflammatory mediators and attenuates inflammation (Huang et al., 2015; O'Neill and Hardie, 2013; Salminen et al., 2011) . Interestingly, AMPK activity is reduced in both obese rodents (Martin et al., 2006) and patients (Viollet et al., 2010; Xu et al., 2012) , in part explaining reduced energy expenditure in obesity.
Numerous studies in both rodent models and humans indicate that obesity generates a state of chronic inflammation in adipose tissue, which in turn leads to insulin resistance and type 2 diabetes (Reilly and Saltiel, 2017; Weisberg et al., 2003; Xu et al., 2003) . This inflammation is generated by recruitment and activation of immune cells, especially proinflammatory macrophages (Lumeng and Saltiel, 2011; Weisberg et al., 2003) . Monocyte chemotactic protein 1 (MCP1/Ccl2) is produced by adipocytes during obesity and is required for macrophage infiltration (Kamei et al., 2006; Kanda et al., 2006) . In turn, proinflammatory cytokines secreted by immune cells in adipose tissue disrupt insulin action in adipocytes (Hotamisligil et al., 1995; Hotamisligil et al., 1994 Hotamisligil et al., , 1996 .
The nuclear factor kB (NF-kB) signaling pathway plays an important role in the development of inflammation and insulin resistance in adipose tissue (Arkan et al., 2005; Baker et al., 2011; Chiang et al., 2009) . NF-kB is activated by the canonical IkB kinases (IKKs), IKKa and IKKb, which phosphorylate IkB, leading to its degradation and release of NF-kB (Lawrence, 2009) . Unlike IKKa and b, the noncanonical IKKs, IKKε, and TBK1 are induced downstream of NF-kB activation . TANK-binding kinase 1 (TBK1) also can be activated by phosphorylation in response to proinflammatory cytokines or other substances that bind to Toll-like receptors 3 and 4 (Perry et al., 2004) , although the upstream kinase that phosphorylates TBK1 remains unknown. Previous studies from our group showed that the activities of IKKε and TBK1 are significantly increased in adipose tissue of HFD-fed mice and further that IKKε deficiency partially protects mice from HFD-induced systemic inflammation, insulin resistance, and hepatic steatosis (Chiang et al., 2009 ). However, how TBK1 might influence glucose metabolism and energy homeostasis remains uncertain.
Here, we report that Tbk1 expression and activity are significantly increased in mature adipocytes of HFD-fed mice. To investigate the roles of adipocyte TBK1, we generated adipocyte-specific TBK1 knockout (ATKO) mice, because wholebody KO of TBK1 is lethal (Delhase et al., 2012) . Adipose-specific TBK1 deficiency attenuates HFD-induced obesity, due to dramatically increased oxygen consumption and energy expenditure in white adipose tissue of obese, but not normal weight, mice. This was explained by increased activity of AMPK. In vitro studies revealed that AMPK is a direct substrate of TBK1 and further that TBK1 mediates the tumor necrosis factor alpha (TNF-a)-induced repression of AMPK activity. At the same time, AMPK activation reciprocally increased the activity of TBK1; this effect is indirect and mediated by the AMPK downstream kinase ULK1, which directly phosphorylates TBK1 at Ser172. This infers a negative feedback loop in which AMPK activity is limited when activated, perhaps explaining in part the repression of energy expenditure during caloric restriction. Surprisingly, TBK1 KO in adipocytes led to increased activation of NF-kB, with upregulation of MCP1 production from adipocytes and macrophage infiltration into adipose tissue, accompanied by exaggerated insulin resistance in HFD-fed mice. The antiinflammatory effect of TBK1 is mediated by phosphorylation of NIK, which results in its degradation and reduced activity of the atypical NF-kB pathway. The loss of TBK1 thus substantially attenuates the AMPK-induced negative regulation of NF-kB, showing that TBK1 is essential for the inhibitory crosstalk between AMPK and proinflammatory signaling. Taken together, these data reveal an unexpected role for TBK1 in both feedback and bidirectional crosstalk between energy sensing and inflammatory pathways in adipocytes to ensure energy homeostasis.
RESULTS

Adipocyte-Specific TBK1 Deficiency Increases Energy Expenditure and Attenuates HFD-Induced Obesity
We previously demonstrated that TBK1 activity is induced by TNF-a and increased in adipose tissue of high-fat diet (HFD)-fed mice . Here, we show that Tbk1 expression is significantly upregulated in mature adipocytes derived from both inguinal (iWAT) and epididymal WAT (eWAT) in HFD-fed compared to normal diet (ND)-fed mice ( Figure 1A ). We generate adipocyte-specific TBK1 KO mice by crossing floxed TBK1 (Flox) mice with adiponectin-Cre mice. ATKO mice have greater than a 50% decrease of Tbk1 mRNA in both eWAT and iWAT, without any change of expression in the liver (Figure 1B) , reflecting complete reduction of TBK1 in adipocytes, with residual protein present in other adipose tissue cells (Jeffery et al., 2014) .
Adipocyte-specific TBK1 KO has no effect on body weight or composition in ND-fed mice ( Figures S1A-S1E ). However, TBK1-deficient mice tend to be leaner and have a lower body weight when fed a HFD, although this difference was not statistically significant ( Figures 1C-1E ). DEXA scanning revealed that ATKO mice have significantly less fat mass ( Figures 1D, 1F , and 1G). In addition, weights of both eWAT and iWAT were significantly reduced in ATKO mice, with no difference in brown adipose tissue (BAT) or liver (Figures 1C and 1H) .
While TBK1 deficiency did not affect oxygen consumption rate (OCR) or energy expenditure (EE) in ND-fed mice (Figures 1I and 1J) , ATKO mice exhibited dramatically increased OCR and EE after HFD ( Figures 1K and 1L) . Although a HFD inhibited OCR and EE in both Flox and ATKO mice, TBK1 deficiency significantly attenuated the reduction of OCR observed after a HFD. TBK1 KO did not affect respiratory exchange rate (RER) or activity in either ND-or HFD-fed mice (Figures S1F-S1I). Moreover, adipocyte-specific TBK1 KO had no effect on food intake (Figure S1J) or body temperature ( Figure S1K ) of ND-or HFD-fed mice.
TBK1 Deficiency Upregulates Mitochondrial Biogenesis
by Attenuating the Inflammation-Induced Inhibition of AMPK Activity in Adipose Tissues in Mice on a HFD Adipocyte size was significantly decreased in HFD-fed ATKO mice (Figure 2A) , suggesting that TBK1 deficiency attenuates HFD-induced adipocyte hypertrophy. Loss of TBK1 significantly increased ex vivo OCR in both WATs of HFD-fed mice (Figure 2B ). This increase was accompanied by a significant upregulation of mitochondrial biogenesis genes such as Ppargc1a, as well as the mitochondrial genes Ndufs7, Cox4i1, Cox5b, Cox8a , and Atp5d, all of which belong to different complexes in the respiratory chain ( Figures 2C and 2D) . Moreover, expression of the thermogenic gene Ucp1 did not change ( Figure 2D ), a finding consistent with no major change in body temperature in ATKO mice. There was no effect on mitochondrial biogenic and thermogenic genes expression in BAT ( Figure S2A ).
Recent studies have identified a creatine-driven pathway that increases EE and thermogenesis (Kazak et al., 2015) , and mice lacking this cycle have reduced EE and greater HFD-induced obesity (Kazak et al., 2017) . There was significant upregulation of Ckmt1 expression in eWAT and Gamt expression in iWAT, suggesting increased activity of the creatine cycle in ATKO mice (Figures S2B and S2C) . Staining of WATs with MitoTracker also confirmed a substantial increase of mitochondria in adipocytes of HFD-fed ATKO mice ( Figure 2E ). Likewise, NAD/NADH ratio was significantly increased in eWAT, and only slightly increased in iWAT from ATKO mice ( Figure 2F ). The significant upregulation of hormone sensitive lipase (HSL/Lipe) and adipose triglyceride lipase (ATGL/Pnpla2) in iWAT, but not eWAT ( Figures S2D and S2E) , could lead to elevation of lipolysis and lipid oxidation in iWAT, potentially attenuating the elevation of NAD/NADH ratio produced by increased mitochondrial biogenesis. Taken together, our data indicate a mitochondria-driven increase of catabolism in WATs of ATKO mice.
Sympathetic activation of adipose tissue increases cAMP levels, and induces mitochondrial biogenesis (Wu et al., 1999) . TBK1 KO did not affect cAMP levels in HFD-fed mice ( Figure S2F) , nor was there a change in response to b-adrenergic stimulation ( Figures S2G and S2H ), suggesting that TBK1 plays no role in controlling catecholamine sensitivity, unlike that proposed for IKKε . While a slight increase of basal lipolysis in iWAT was observed because of upregulated expression of Lipe and Pnpla2 (Figure S2H and S2E) , TBK1 deficiency did not affect serum triglycerides and nonesterified fatty acid (NEFA) concentrations (Figures S2I and S2J) . However, TBK1 deficiency substantially upregulated AMPK Thr172 phosphorylation in both eWAT and iWAT, but not BAT, of HFD-fed ( Figures 2G, 2H , and S2K), but not NDfed ( Figures S2M and S2N ), mice. The lack of effect on BAT is likely because TBK1 expression is not significantly induced in BAT that has lower inflammation ( Figure S2L ). There was no difference in AMP/ATP or ADP/ATP ratios between HFD-fed ATKO and Flox mice (Figures S2O and S2P) .
HFD feeding significantly decreased AMPK Thr172 phosphorylation in adipose tissue ( Figure 2I ). TNF-a decreased AMPK Thr172 phosphorylation within 30min in adipocytes ( Figure 2J ). TBK1 deficiency in both differentiated primary preadipocytes and murine embryonic fibroblasts (MEFs) abrogated inhibition of AMPK activation by TNF-a ( Figures 2K and S2Q) . Thus, since TBK1 levels and activity are increased during obesity, these in vivo and in vitro observations suggest that the decrease in AMPK activity observed in obesity is mediated by TBK1, which is elevated by HFD-induced adipose inflammation, and thus may represent a major mechanism of the obesitydependent reduction in AMPK activity in fat tissue.
TBK1 Directly Phosphorylates AMPK a Subunit to Inhibit AMPK Actsivity We examined whether TBK1 interacts with AMPKa to inhibit its activity. Overexpression of TBK1 wild-type (WT), but not TBK1 K38A kinase-dead mutant (KD), substantially decreased AMPKa1 Thr172 phosphorylation. AMPKa1 directly interacts with both TBK1 WT and TBK1 KD ( Figure 3A) . Moreover, overexpression of TBK1 WT, but not TBK1 KD, resulted in a shift of AMPKa1 band (Figure 3A) . Lambda protein phosphatase treatment of immunoprecipitated AMPKa1 abolished the shift produced by TBK1 WT (Figure 3A) , indicating that TBK1 directly interacts with and phosphorylates the AMPKa1 subunit to inhibit its activation. The AMPKa1 protein from cells overexpressing AMPKa1/TBK1 WT and AMPKa1/TBK1 KD was subject to phospho-amino acid analysis by LC-MS/ MS, revealing two phosphorylation sites (Ser459 and Ser476) on AMPKa1 from cells overexpressing AMPKa1 with TBK1 WT, but not the KD mutant (Figures 3B and S3A-S3C; Table S1 ). Both Ser459 and Ser476 are conserved between AMPKa1 (PRKAA1) and AMPKa2 (PRKAA2) isoforms ( Figure 3C ) and among species from Drosophila to human (Figure 3D) . We generated Ser/Ala nonphospho-mimetic (SS/AA) and Ser/Asp phospho-mimetic (SS/DD) mutants for both sites. Overexpression of HA-AMPKa1 WT or mutants with Flag-AMPKb1 and Myc-AMPKg1 demonstrated that the SS/ AA mutation increased, while the SS/DD mutation decreased AMPKa1 Thr172 phosphorylation ( Figures 3E and 3F ), suggesting that TBK1-induced phosphorylation of AMPKa1 Ser459 and Ser476 inhibits AMPK activation, in turn repressing energy expenditure in obesity ( Figure 3G ). The TBK1 phosphorylation sites in the AMPKa subunit are close to, but distinct from, inhibitory sites phosphorylated by Akt and GSK-3, both of which also inhibit AMPK activity (Suzuki et al., 2013) . Both phosphorylation sites identified by our study are located close to b subunitinteracting domain and ST loop of the AMPKa subunit. Previous studies have shown that the interaction between AMPKa and b subunits affect AMPK Thr172 phosphorylation and activation (Garcia-Haro et al., 2010), and AMPKb KO causes a loss of AMPKa in fat tissue (Mottillo et al., 2016) . Phosphorylation within the ST loop may induce a conformational change (Hawley et al., 2014) , or recruit a phosphatase to decrease Thr172 phosphorylation (Suzuki et al., 2013) .
TBK1 Is Stimulated by Activation of AMPK
Since caloric restriction reduces energy expenditure to defend body weight (Martin et al., 2007) , we sought to determine whether TBK1 might contribute to the reduction of energy expenditure during caloric restriction via repressing AMPK. We treated WT and AMPKa1/a2 KO MEFs with the TLR4 agonist lipopolysaccharides (LPS) or the AMPK activator AICAR. AICAR treatment resulted in activating phosphorylation of TBK1 at Ser172 in WT, but not AMPKa1/a2 KO, MEFs, while LPS remained effective ( Figure 4A ). Additionally, treatment of 3T3-L1
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adipocytes with AICAR also increased TBK1 phosphorylation, and this increase was attenuated by pretreatment with the AMPK inhibitor compound C ( Figure 4B ). Co-overexpression of AMPKa1 or a2 with AMPKb1 and g1 subunits increased TBK1 phosphorylation in HEK293T cells ( Figures S4A and S4B ). These data indicate that activation of AMPK stimulates TBK1 activating phosphorylation in vitro.
To examine AMPK-stimulated TBK1 phosphorylation in vivo, we generated adipocyte-specific AMPKa1/a2 double-KO mice (a1/a2 AKO). AICAR injection induced TBK1 Ser172 phosphorylation in adipose tissue of AMPK FL/FL mice, but not a1/a2 AKO mice ( Figure 4C ). Moreover, we found that Tbk1 expression is significantly induced by fasting ( Figure S4C ). Taken together, these data demonstrate that activation of AMPK under catabolic conditions produces TBK1 phosphorylation and activation both in vitro and in vivo, suggesting that TBK1 activity is increased by both inflammatory and catabolic signals.
We were unable to demonstrate a direct phosphorylation of TBK1 by recombinant AMPK, suggesting existence of an intermediate kinase. Since both TAK1 and ULK1 have been reported as downstream effectors of AMPK, we pretreated 3T3-L1 adipocytes with the TAK1 inhibitor oxozeaenol (Oxo) or the ULK1 inhibitor SBI-0206965 (SBI), followed by treatment with AICAR. Inhibition of ULK1 with SBI-0206965 attenuated AICAR-induced TBK1 phosphorylation, while Oxo had no effect ( Figure 4D ), suggesting that ULK1 mediates the phosphorylation of TBK1 stimulated by AMPK. Moreover, AICAR-stimulated TBK1 phosphorylation was completely abrogated in ULK1-deficient MEFs (Figure 4E ). We generated adipocyte-specific ULK1 KO (ULK1 AKO) mice, and injected ULK1 FL/FL and ULK1 AKO mice with AICAR. While AICAR treatment stimulated TBK1 phosphorylation in adipose tissue of ULK1 FL/FL mice, loss of ULK1 abrogated the effect of AICAR ( Figure 4F ). Additionally, an in vitro kinase assay was performed to test if ULK1 directly phosphorylates TBK1 Ser172. Immunoprecipitated TBK1 WT was pretreated with lambda protein phosphatase to reduce basal phosphorylation, and then incubated with ULK1. Active ULK1 directly phosphorylated both TBK1 WT and its KD mutant (Figure 4G) . These data conclusively demonstrate that ULK1 directly phosphorylates TBK1 Ser172 and mediates the activation of TBK1 phosphorylation produced by AMPK activation both in vitro and in vivo (Figure 4H) .
We sought to examine if the ULK1/TBK1 axis mediates negative feedback regulation of AMPK. 2-hr glucose starvation induced AMPK Thr172 phosphorylation in both WT and ULK1 KO MEFs, but was significantly higher in ULK1 KO cells (Figure S4D) . Additionally, glucose starvation increased TBK1 Ser172 phosphorylation in WT, but not in ULK1 KO, MEFs (Figure S4D ). These results indicate that upon its phosphorylation and activation by AMPK, ULK1 initiates a negative-feedback loop to regulate AMPK activity by phosphorylation and activation of TBK1. These data suggest that the ULK1/TBK1 axis normally limits AMPK activity to preserve energy storage.
Adipocyte-Specific TBK1 KO Mice Have Exaggerated HFD-Induced Glucose Intolerance and Insulin Resistance, along with Increased Adipose Inflammation TBK1 deficiency did not significantly affect fasting glucose or insulin levels in ND mice. However, both fasting blood glucose and insulin tended to be slightly higher in HFD-fed ATKO mice (Figures S5A and S5B) . Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) showed no difference between the genotypes in ND-fed mice ( Figures S5C and S5D) . Surprisingly, TBK1 deficiency exaggerated glucose intolerance and insulin resistance in HFD-fed mice ( Figures 5A and 5B ), without significant effects on insulin levels during GTT ( Figure S5E ). Because there was no difference in hepatic steatosis and liver gene expression in ATKO mice on HFD ( Figures S5F and S5G ), we examined whether glucose intolerance was due to decreased insulin-stimulated glucose uptake in adipose tissues by in vivo glucose uptake assay. Adipose tissue glucose uptake was significantly decreased in both eWAT and iWAT of HFD-fed ATKO mice ( Figure 5C ). This was accompanied by reduced insulin-stimulated Akt phosphorylation in adipose tissue of TBK1-deficient mice ( Figure 5D ).
Increased adipose inflammation and macrophage infiltration inhibit insulin-stimulated glucose uptake and result in insulin resistance (Hotamisligil et al., 1993; Weisberg et al., 2003) . Adipose expression of macrophage markers F4/80 (Adgre1), CD11c (Itgax), and CD206 (Mrc1) were significantly induced by HFD feeding in Flox mice. TBK1 deficiency further increased expression of macrophage marker genes ( Figure 5E ). H&E and F4/80 staining of adipose tissue showed a substantial increase of adipose macrophage infiltration in ATKO mice (Figure 5F ). Staining and fluorescence-activated cell sorting (FACS) analysis of stromal vascular fractions (SVFs) from eWAT with F4/80 antibody revealed a significant increase of macrophages in HFD-fed ATKO mice ( Figures 5G and 5H ). MCP1 (Ccl2) plays an essential role in the induction of adipose macrophage infiltration (Kanda et al., 2006) . Ccl2 expression was significantly upregulated in adipose tissue ( Figure 5I ) and in mature adipocytes of HFD-fed ATKO mice ( Figure 5J ). Further analysis revealed that TBK1 deficiency exaggerated HFD-induced expression of Tnfa in eWAT ( Figure 5K ). Taken together, these data indicate that TBK1 deficiency in adipocytes increases the recruitment of proinflammatory macrophages into adipose tissue, releasing inflammatory cytokines such as TNF-a to block insulin action.
Loss of TBK1 Increases TNF-a-Induced NF-kB Activation in HFD-Fed Mice To understand the underlying mechanism of increased inflammation in ATKO mice, we examined NF-kB signaling in adipose tissues. Compared to Flox controls, there was an increase in p52, the active form of NF-kB, as well as phosphorylation of p105 in eWAT and iWAT, but not BAT, of HFD-fed ATKO mice or WATs of ND-fed ATKO mice ( Figures 6A, 6B , and S6A-S6C). To deter- mine whether the hyperactivation of NF-kB caused by TBK1 deficiency was cell autonomous, we differentiated primary preadipocytes from Flox and ATKO mice and treated with TNF-a for 2 or 8 hr. TBK1 KO significantly increased TNF-a-induced p52 generation and p105 phosphorylation ( Figures 6C and S6D) . Furthermore, Ccl2 expression induced by 16 hr TNF-a treatment was significantly increased in TBK1-deficient differentiated preadipocytes and MEFs ( Figures  6D and S6E ), although TBK1 deficiency did not affect acute NF-kB activation up to 1hr of TNF-a treatment ( Figure S6F ). Taken together, these data indicate that TBK1 KO affects TNF-a-induced NF-kB activity only after 2 hr of treatment, strongly suggesting that the effects of TBK1 KO are dependent on gene expression or protein degradation.
NF-kB-inducing kinase (NIK) phosphorylates and activates IKKa homodimers and to a lesser extent IKKa/b heterodimers. The activated IKKa/IKKa homodimer phosphorylates p100 to induce its cleavage and generate p52, while the activated IKKa/IKKb heterodimer phosphorylates p105 (Sun, 2011; Zarnegar et al., 2008) . A previous study suggested that TBK1 phosphorylates NIK, and induces its degradation to attenuate NF-kB activation (Jin et al., 2012) . Overexpression of TBK1 WT, but not KD, decreased NIK protein ( Figure S6G ).
Co-immunoprecipitation experiments confirmed that NIK directly interacts with both TBK1 WT and its KD mutant (Figure S6H) . Unfortunately, the currently available NIK antibody was not able to detect endogenous NIK without MG132 treatment. We used CRISPR/Cas9 to knock out NIK in immortalized WT and TBK1 KO MEFs ( Figure S6I ). NIK KO attenuated TNFa-induced activation of NF-kB, and abrogated NF-kB hyperactivation caused by TBK1 deficiency ( Figure 6E ). NIK KO significantly attenuated TNF-a-induced Ccl2 expression, and abrogated increased Ccl2 expression in TBK1 KO cells (Figure 6F ). These results demonstrate that TBK1 attenuates TNFa-induced NF-kB activation and Ccl2 expression via regulating NIK degradation, and strongly suggest that increased inflammation in TBK1 KO adipocytes is due to increased levels of NIK and hyperactivation of NF-kB. Our study thus reveals a counter-inflammatory role of TBK1, which controls TNFa-induced NF-kB activation in a negative feedback loop, and maintains inflammation at low levels, typical of obesity-induced inflammation ( Figure 6G ).
TBK1 Deficiency Attenuates Inhibition of NF-kB
Signaling by AMPK Activation of AMPK reduces production of inflammatory cytokines and attenuates inflammation (Huang et al., 2015; Salminen et al., 2011) , although the underlying mechanism is unknown. Because TBK1 can be activated downstream of AMPK, and since loss of TBK1 abrogates the feedback inhibition of inflammation, we explored the hypothesis that TBK1 mediates the anti-inflammatory effect of AMPK activation. We pretreated adipocytes with AICAR, and then treated cells with TNF-a to examine activation of NF-kB signaling. AICAR attenuated TNF-a-induced phosphorylation of p105 and IKKa/b in adipocytes ( Figure 7A ), and decreased TNF-a-induced Ccl2 expression ( Figure 7B ). TBK1 deficiency abrogated the inhibitory effect of AICAR on TNF-a-induced p105 and IKKa/b phosphorylation ( Figures 7C and S7A ). AICAR-induced inhibition of Ccl2 expression was significantly attenuated in TBK1 KO cells ( Figures 7D and S7B ). To confirm that attenuation of the anti-inflammatory effects of AICAR is due to loss of TBK1, immortalized TBK1 KO MEFs were transfected to express GFP or TBK1. In TBK1 KO MEFs, expression of TBK1 restored inhibition of p105 and IKKa/b phosphorylation by AMPK activation (Figure 7E) . We conclude that TBK1 mediates the anti-inflammatory effects of AMPK activation via attenuation of NF-kB activity ( Figure 7F ). Taken together, our findings demonstrate that TBK1 operates at the intersection of two crucial pathways to mediate both the repression of energy expression by inflammation and the attenuation of inflammation by AMPK activation.
DISCUSSION
We demonstrate here a previously unappreciated role for the protein kinase TBK1; upon its induction and activation during obesity and caloric restriction, TBK1 represses energy expenditure while also attenuating inflammation in adipocytes and surrounding cells in adipose tissue, thus operating at the intersection of inflammation and energy homeostasis. We conclude that TBK1 mediates both feedback and bi-directional inhibitory crosstalk between AMPK and inflammation ( Figure S7C ). Numerous studies have demonstrated that obesity in both rodents and patients is associated with reduced energy expenditure (Hill et al., 2012) . However, the mechanisms by which energy expenditure is reduced in obesity is unknown. Data shown here suggest that adipose tissue inflammation may play an important role, at least partially through the induction of TBK1.
Several studies have implicated a central role for the NF-kB pathway in triggering and sustaining the deleterious effects of overnutrition on energy homeostasis (Baker et al., 2011) . Although TBK1 displays significant sequence homology to the other IKKs (Clé ment et al., 2008) , and although TBK1 is activated by pro-inflammatory stimuli, the kinase is completely dispensable for NF-kB activation. Interestingly, we found that Tbk1 expression is significantly upregulated in mature adipocytes of HFD-fed mice, suggesting that it might be an effector of inflammation. Moreover, the specific IKKε/TBK1 inhibitor amlexanox alleviates many of the effects of HFD feeding and genetic obesity, improving weight, insulin sensitivity, inflammation, and hepatic steatosis , along with a substantial, clinically relevant improvement in blood sugar and glucose hemostasis in a subset of obese type 2 diabetic patients with underlying inflammation (Oral et al., 2017) . As we have already studied IKKε KO mice (Chiang et al., 2009) , these findings prompted us to create adipocyte-specific TBK1 KO mice to evaluate the role of TBK1 in metabolic homeostasis. Adipocyte-specific TBK1 KO ameliorates HFD-induced obesity via increasing oxygen consumption rates and energy expenditure, and like the IKKε/TBK1 inhibitor amlexanox , has no effect on normal weight mice. What is the mechanism by which attenuation of AMPK activity by TBK1 represses energy expenditure? Numerous studies have indicated that AMPK increases lipid oxidation, while inhibiting lipogenesis through reduced activity of mTORC1 (Gwinn et al., 2008) , and increases mitochondrial biogenesis (Reznick and Shulman, 2006) . Increased AMPK activity in HFD-fed ATKO mice increases expression of Pparc1a and other genes involved in respiration, including a substantial increase of mitochondrial biogenesis in adipocytes. Thus, these findings illuminate how obesitydependent chronic inflammation reduces energy metabolism via TNF-a-induced inhibition of AMPK activity in adipose tissues. TBK1 Ser172 phosphorylation is increased by pro-inflammatory cytokines and ligands that bind to TLR3 and TLR4 (Perry et al., 2004) , and structural studies show that TBK1 is activated by transautophosphorylation (Ma et al., 2012) . We show here that TBK1 is surprisingly activated by AMPK via its downstream protein kinase ULK1. ULK1 is thus the first TBK1 kinase discovered. Although ULK1 is a key regulator of autophagy (Russell et al., 2013) , the discovery of the AMPK/ULK1/TBK1 axis indicates that ULK1 may have other important functions. More importantly, under conditions in which TBK1 is expressed, AMPK activation may be self-limiting through this feedback loop. Moreover, TBK1 may limit energy expenditure during caloric restriction (Leibel et al., 1995) , in which absolute restriction of food intake in patients resulted in reduced energy expenditure, in an attempt to defend body weight. This finding also has important implications for the discovery and development of AMPK activators for the treatment of metabolic disease, and suggests that a combination of AMPK activators with TBK1 inhibitors such as amlexanox might be synergistic.
Despite increasing energy expenditure, TBK1 KO exaggerated HFD-induced glucose intolerance and insulin resistance, likely due to enhanced adipose inflammation and macrophage infiltration in HFD-fed ATKO mice (Hotamisligil et al., 1993; Weisberg et al., 2003) . TBK1 deficiency increased TNF-a-induced p105 phosphorylation and generation of p52 in a cell-autonomous manner, and upregulated TNF-a-induced Ccl2 expression. Increased MCP1 production is the primary signal for macrophage infiltration in adipose tissue in obesity (Kamei et al., 2006) . KO of NIK by CRISPR/Cas9 confirmed that the TBK1 deficiency-induced hyper-response to TNF-a is dependent on NIK. However, while NIK KO did not completely abrogate TNFa-induced NF-kB activation and Ccl2 expression, it completely abolished the difference between WT and TBK1 deficient cells, suggesting that TBK1 mainly controls the atypical pathway for NF-kB activation. Moreover, these data also indicate that TBK1 does not affect the initiation of inflammation in obese mice, but limits its development, perhaps accounting for the low-grade nature of adipose tissue inflammation in obesity (Xu et al., 2003) . In addition, studies have shown that extracellular ATP exerts a pro-inflammatory effect (Cauwels et al., 2014) , synergistic with the effect of TNF-a (Schnurr et al., 2000) . Thus, in HFD-fed ATKO mice, increased AMPK-induced ATP synthesis and TNF-a-stimulated ATP release (Lohman et al., 2015) may exacerbate adipose inflammation via increasing extracellular ATP. The increased ATP release might also explain why intracellular ATP in adipocytes of HFD-fed ATKO mice remains stable, despite a dramatic increase in mitochondrial number and activity.
It is important to note that the IKKε/TBK1 inhibitor amlexanox also increases energy expenditure in rodents , and was effective in lowering blood sugar in a subset of obese patients with type 2 diabetes (Oral et al., 2017) . Interestingly, analysis of gene expression changes in adipose tissue from responding patients revealed many of the same changes in mitochondrial respiration genes observed here in ATKO mice, suggesting that at least a part of amlexanox's beneficial effects might be due to increased AMPK activity via TBK1 inhibition. However, unlike the ATKO mice, amlexanox treatment improves catecholamine sensitivity in adipose tissue , while reducing insulin resistance and adipose tissue inflammation . We reported that IKKε KO increases thermogenesis and energy expenditure, while reducing adipose inflammation (Chiang et al., 2009) . It is likely that IKKε is responsible for adipocyte catecholamine resistance via phosphorylation of PDE3B , and must be inhibited to improve glucose homeostasis and inflammation. However, IKKε has no effect on AMPK phosphorylation. During HFD-feeding, expression of both Ikbke and Tbk1 are upregulated by inflammation. While IKKε phosphorylates and activates PDE3B to induce catecholamine resistance, TBK1 inhibits AMPK activity to reduce catabolism via this pathway. The combination of IKKε and TBK1 activation thus decreases energy expenditure to exaggerate energy storage and obesity. Thus, we propose that the beneficial metabolic effects of amlexanox require inhibition of both IKKε and TBK1.
Previous studies showed that activation of AMPK by energy stresses, such as caloric restriction, reduces adipose inflammation and improves glucose metabolism (Cantó and Auwerx, 2011; Larson-Meyer et al., 2006) . We show here that loss of TBK1 disrupts the anti-inflammatory effects of AMPK activation. As TBK1 induces NIK degradation to attenuate NF-kB activation, we conclude that TBK1 mediates the anti-inflammatory functions of AMPK via negatively regulating NF-kB activation.
Taken together, these data have introduced a new player in the control of energy homeostasis under conditions of both over-and undernutrition. Upon its activation, TBK1 can repress respiration by inhibiting AMPK activity, perhaps explaining in part why energy expenditure is reduced in states of obesity. At the same time, TBK1 can attenuate inflammation after it is induced by obesity, maintaining the inflammatory state at a low-grade level. Finally, TBK1 plays a crucial role in a feedback loop, both limiting the activity of AMPK under conditions, such as caloric restriction, in which it is activated but also mediating the anti-inflammatory effects of this important energy sensor. While many questions remain, these insights open a new line of investigation concerning how TBK1 modulates energy homeostasis.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Animals
Tbk1 fl/fl mice were bred with adiponectin-cre mice to generate adipocyte-specific TBK1 KO mice. Adipocyte-specific AMPKa1/a2 double KO mice were generated by breeding Prkaa1 fl/fl mice and Prkaa2 fl/fl mice to adiponectin-cre mice.
Adipocyte-specific ULK1 KO mice were created by breeding Ulk1 fl/fl mice to adiponectin-cre mice. All the mice have C57BL/ 6J background. Only male mice were used for experiments. We fed mice with normal chow diet or high fat diet consisting of 45% of calories from fat (D12451 Research Diets Inc.) for 12-16 weeks, starting at 6-8 weeks of age. During metabolic studies, ear tag numbers were used to identify animals. Flox and KO mice are littermates and cage mates. Researchers performing test and collecting data were blinded during experiments. Animals in each cohort were produced from 20 breeding pairs to minimize the birthdate range. Mice were housed in a specific pathogen-free facility with a 12-h light, 12-h dark cycle, and given free access to food and water, except for fasting period. All animal use was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California-San Diego. For metabolic study, mice are subject to CLAMs indirect calorimetry and dual energy X-ray absorptionmetry (DEXA) scanning at ACP phenotyping core of UCSD. Rectal temperature was measured by Model 4600 Thermometer (Alpha Technics). Serum insulin was measured with Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem).
Cells
3T3-L1 adipocytes
Murine 3T3-L1 preadipocytes were grown to 2 days after confluence in Dulbecco's Modified Eagle's Media (DMEM) with 10% newborn calf serum (NCS). 0.5mM 3-isobutyl-methylxanthine, 1 mM dexamethasone, and 1 mg/ml insulin (MDI) cocktail were used to induce preadipocytes differentiation in DMEM containing 10% fetal bovine serum (FBS) for the first 3 days. Cells were cultured in media containing insulin for another 3 days. After 48hrs, the media was replaced by DMEM with 10% FBS. Finally, differentiation was completed in the media containing 10% FBS (Zhao and Stephens, 2013) . For serum deprivation, media was change to DMEM containing 0.2% BSA or low-glucose DMEM containing 0.2% BSA. Only cultures in which > 90% of cells displayed adipocyte morphology were used.
Differentiation of primary preadipocytes
Inguinal adipose tissues of 4-6 weeks old male mice were minced and digested with 1mg/ml type II collagenase for 25 min at 37 C with gentle agitation. Cells were washed, filtered through 100 mm filter. After centrifugation, SVF was plated on 10cm collagen-coated cell culture plate. After 2 rounds of culture, Preadipocytes were grown to confluence and induced to differentiate with 0.5mM 3-isobutyl-methylxanthine, 1 mM dexamethasone, 1 mg/ml insulin (MDI) cocktail and 1 mM rosiglitazone (Cayman).
Immortalization of TBK1 KO MEFs
To immortalize cells, they were transduced with retroviruses encoding a temperature-sensitive (tsa58) mutant A438V of large T antigen. After antibiotic selection with 100 mg/ml G418 at the permissive temperature of 33 C for two weeks, cells were trypsinized and transferred to new culture dishes. Cells were moved to 37 C incubation 48hrs before experiments to eliminate expression of SV40 large T antigen.
Generation of NIK KO MEFs
Immortalized WT or TBK1 KO MEFs were transduced with viral supernatant to express gRNA/Cas9 (gRNA: 5 0 -GGCAAAATGGC CCGTGTGTGC-3 0 ). Supernatants were centrifuged to remove cell debris, and supplemented with Polybrene (8 mg/ml) before adding to cells. After antibiotic selection with 2.5 mg/ml puromycin for two weeks, cells were trypsinized and transferred to new culture dishes. Reconstitution of TBK1 in TBK1 KO MEFs Immortalized TBK1 KO MEFs were transduced with viral supernatants to express GFP or TBK1. Supernatants were centrifuged to remove cell debris, and supplemented with Polybrene (8 mg/ml) before adding to cells. 48hrs after infection, expression of GFP and TBK1 was examined by Microscopy and western blot.
METHOD DETAILS
Gene expression analysis Tissues were homogenized in TRIzol Reagent (Life Technologies). RNA was isolated with PureLink RNA mini kit (Life Technologies). 1 mg of purified RNA was used for reverse transcription-PCR to generate cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystem). DDCt real time PCR with Power SYBR Green PCR Master Mix (Life Technologies) and QuantStudio 5 Real-Time PCR System were used to analyze cDNA. Gapdh was used as endogenous control. Transfection 1 mg DNA for each plasmid was used to transfect HEK239T cells with Lipofectamine 3000 (Life Technologies), according the manufacturer's instruction. 24hrs later, cells were harvested and subject to western blot analysis.
Immunoprecipitation and lambda protein phosphatase treatment Cells were harvested in IP buffer containing 100mM Tris (pH 7.5), 5mM MgCl 2 , 130mM NaCl, 1mM EDTA, 1% Triton X-100 with freshly added protease inhibitors tablet (Roche), and phosphatase inhibitor 2 mM sodium vanadate and 5mM sodium fluoride. Immunoprecipitation was performed with anti-HA or Flag affinity gels (Biotool). Affinity gel was washed with TBS for 3 times and incubated with lambda protein phosphatase (NEB) at 30 C for 30min. After 3 times wash with PBS, protein was eluted with SDS loading buffer at 95 C.
Western blot
Tissues or cells were homogenized in a non-denaturing lysis buffer that contained 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, with freshly added protease inhibitors tablet (Roche), and phosphatase inhibitor 2 mM sodium vanadate and 5mM sodium fluoride. The extract was centrifuged at 9500 g for 10 min at 4 C. Supernatants were collected and analyzed with BCA (Thermo Scientific) to quantify protein content. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). Individual proteins were detected with specific antibodies and visualized on film using horseradish peroxidase-conjugated secondary antibodies (Fisher Scientific) and SuperSignal West Pico Chemilunminescent Substrate (Thermo Scientific). Bands were quantified with ImageJ (NIH).
Glucose tolerance test
Fasting blood glucose were measured after 14hrs fast, using Easy Step Blood Glucose Monitoring System. Mice were then intraperitoneally injected with D-[+]-glucose (Sigma) at a dose of 2g/kg BW for ND-fed mice or 1.2g/kg BW for HFD-fed mice. Blood glucose levels were measured at 15, 30, 45, 60, 90 and 120 min after injection.
Insulin tolerance test
Fasting blood glucose were measured after 4hrs fast, using Easy Step Blood Glucose Monitoring System. Mice were then intraperitoneally injected with insulin (Humulin R) at a dose of 1U/kg BW for ND-fed mice or 1.2U/kg BW for HFD-fed mice. Blood glucose levels were measured at 15, 30, 45, 60, 90 and 120 min after injection.
In vivo 2- [C 14 ]-deoxyglucose uptake Mouse was fasted for 16hrs, and then injected with 1.2g/kg glucose, 1U/kg insulin with 180 mCi/kg 2- [C 14 ]-deoxyglucose. Blood was collected at 0, 15, 30, 45 and 60min. Mice were dissected at 60min. Adipose tissues were collected, weighted, and homogenized in perchloric acid. After centrifugation, supernatant was collected and neutralized. Radioactivity in lysate and serum was determined by the Beckman Coulter.
Histology and determination of adipocyte size Tissues were dissected, and then fixed in 10% formalin. Paraffin-embedding tissues were sectioned and subject to H&E and F4/80 (AbD Serotec) IHC staining at UCSD histology core. Stained tissue was visualized with NanoZoomer Slide Scanner. Size of adipocytes was determined by ImageJ analysis of H&E stained tissues.
Mature adipocytes and SVF separation and FACS Minced white adipose tissue was digested in RPMI with 0.5% BSA containing 1mg/ml type II collagenase for 25 min at 37 C with gentle agitation. The cell suspension was filtered through a 100 mm cell strainer and centrifuged at 500 g for 5 min to separate floating mature adipocytes and SVF. Red blood cells in SVF were lyzed with ACK red blood cell lysis buffer for 5min. SVF was washed with RPMI with 0.5% BSA. Fc receptor was blocked with anti-CD16/CD32 antibody (eBioscience). Cells were stained with anti-F4/ 80-FITC (eBioscience), and analyzed by flow cytometry.
Ex vivo oxygen consumption rate measurement Adipose tissues were dissected, weighted, quickly rinsed in PBS. Minced tissues were placed in 96-well tissue culture plate. Ex vivo oxygen consumption rate was measured with Oxygen Consumption Assay Kit (Abcam) according to the manufacturer's instruction. 150 mL pre-warmed medium and 10 mL oxygen consumption reagent were added to each well. Wells were sealed with pre-warmed high sensitivity mineral oil. Fluorescence was measured at 37 C for 30min by Tecan Infinite M200 Pro.
Mitochondrial staining and confocal microscopy Adipose tissues were dissected and fixed in 10% formalin with 7.5% sucrose. OCT-embedded tissue was sectioned and stained with 200nM Mitotracker Red (Life Technologies) for 45min at room temperature, followed by 3 washes with PBS. Fluorescence was visualized with Olympus FV1000 microscope.
In vitro kinase assay Immunoprecipitated Flag-TBK1 WT or Flag-TBK1 KD was subject to in vitro kinase assay with 40ng/ul ULK1 active kinase (SignalChem), kinase assay buffer III (SignalChem) and 100 mM ATP (SignalChem). After 15min incubation in 30 C water bath, reaction was stopped by adding SDS loading buffer and heating at 95 C. Phospho-TBK1 Ser172 antibody (Cell Signaling) was used to detect phosphorylated TBK1.
NAD/NADH ratio measurement
Tissue NAD/NADH ratio was measured with NAD/NADH Assay kit (abcam). Tissues were dissected, rinsed in PBS, and homogenized in NAD/NADH extraction buffer from the kit. After centrifugation, supernatant was collected. NAD/NADH ratio was measured according to the manufacturer's instruction.
cAMP measurement
Tissue cAMP levels were determined using the cAMP XP Assay kit (Cell Signaling). Tissues were dissected, rinsed in PBS, and homogenized in cell lysis buffer on ice. After centrifugation, supernatant was collected. 50 mL sample was used to determine cAMP level according to the manufacturer's instruction. cAMP level was normalized to protein content.
